Cite
HARVARD Citation
Ross, P. et al. (n.d.). A phase I/II dose finding study evaluating the safety and tolerability of capecitabine and aflibercept in patients with unresectable metastatic colorectal cancer deemed unsuitable for doublet/triplet chemotherapy: results of the phase I study. European journal of cancer. pp. S69-S70. [Online].